News - Page 5 of 34 - MaRS Innovation

Zucara Therapeutics Inc. developing drug to prevent hypoglycemic episodes for people with diabetes

TORONTO and VANCOUVER, CANADA (January 12, 2016) — A novel drug therapy to reduce the severity and frequency of hypoglycemic (low blood sugar) episodes in people with diabetes is being developed by Zucara Therapeutics Inc. This new start-up company, created by MaRS Innovation and The Centre for Drug Research and Development (CDRD) is based on decades of diabetes research by renowned University of Toronto (U of T) professor, Dr. Mladen Vranic. Zucara Therapeutics will attend Does of the Valley in February 2016. The ... Read more

MLA48 Angel Investment Fund Completes Third Investment in UTEST Company

MLA48 leads ConferenceCloud pre-seed round in cooperation with UTEST TORONTO, CANADA (January 11, 2016) — MLA48, Canada’s first angel investment fund committed to providing a 48-hour turnaround on investment decisions, has announced its third investment in ConferenceCloud, an innovative digital platform that provides a virtual solution for the next generation of hybrid conference events. TechVibes and BetaKit covered this announcement. The University of Toronto also published a web story on Olivia and John-Alan Simmons and their start-up journey. Founded in 2014 by siblings Olivia ... Read more

Top 10 Portfolio Stories for 2015

2015 created a flurry of activity for MaRS Innovation and our portfolio. As the holidays begin, here are our picks for the top 10 news stories from MI's portfolio in 2015. We look forward to more exciting developments in 2016. You may also have noticed we've refreshed our website and re-organized how we communicate about our work and services. We'd love to hear your thoughts: contact Elizabeth Monier-Williams. Top 10 MI Portfolio Stories for 2015 1.  ChipCare Corporation, a University of Toronto start-up company ... Read more

UTEST grad eQOL receives $350,000 for remote patient monitoring program

UTEST graduate eQOL has received $350,000 from the Ontario Government to support patients managing their kidney dialysis at home. eQOL's solutions use mobile tablets technology to support patients in managing independent care at home. The funding, part of an Ontario Centres of Excellence program to support technology used to remotely monitor and care for Ontario patients, was announced December 1, 2015 and covered in Canadian Healthcare Technology. eQOL has partnered with London Health Sciences Centre, Ontario Telemedicine Network and the Kidney Foundation of Canada ... Read more

Triphase to present Marizomib clinical and preclinical data at American Society of Hematology’s annual meeting

TORONTO and SAN DIEGO (December 8, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that positive results from its ongoing Phase 1 proof-of-concept study evaluating marizomib in patients with relapsed and refractory multiple myeloma will be presented at the 57th Annual Meeting of the American Society of Hematology (ASH). The company will also present preclinical data on marizomib demonstrating synergistic activity in combination with pomalidomide. Marizomib is a novel ... Read more

University of Toronto sperm selection technology featured in the Toronto Star

"In a project spearheaded by PhD candidate Reza Nosrati, U of T researchers are trying to learn more about the way sperm cells move — something that could benefit those using in vitro fertilization (IVF)," writes Daniel Otis in "Sperm show U of T researchers a new trick: slithering" published in the Toronto Star on November 13, 2015. MaRS Innovation is working with Professor David Sinton, Nosrati and the university's Innovations and Partnerships Office to commercialize the technology for the human sperm ... Read more

Triphase secures FDA orphan drug designation for Marizomib in Malignant Glioma

TORONTO and SAN DIEGO (November 19, 2015) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for marizomib to treat patients with malignant glioma. Malignant glioma is an aggressive form of brain cancer for which there is a significant unmet need in current treatments due to the disease's poor prognosis. Triphase is evaluating marizomib, a novel and highly ... Read more

Flybits named to Deloitte’s Technology Fast 50 Companies to Watch

Flybits, a Ryerson University start-up company created in partnership with MaRS Innovation, has been named to Deloitte's Technology Fast 50 Companies to Watch list. According to TechVibes, "Companies were selected for their technological innovation, entrepreneurship, leadership and growth. Now in its 18th year, Technology Fast 50 celebrated companies with an average four-year growth rate of 1,293%." You can read TechVibes' coverage of the Deloitte announcement here. The full list, of which 62% are software companies, is posted on Deloitte's website. (more…) Read more

UTEST cited among Toronto’s top 10 tech accelerators

UTEST, the tech accelerator co-directed by MaRS Innovation and the University of Toronto, was named to BlogTO's Top 10 list of technology accelerators on November 8, 2015. The list was published just weeks before the announcement of the fourth UTEST cohort, and included recognition of TrendMD and Whirlscape as notable startups among the graduated UTEST companies. Here's the excerpt: UTEST, a collaboration between U of T and MaRs Innovation, is in its fourth year of operation with 15 teams. The program is one year ... Read more

TrendMD’s recommendation engine now reaches 70 STEM publishers, 12 million readers

TrendMD's content recommendation engine, an innovative content marketing solution, delivered 450,000 article readers last month Faced with the challenge of finding research they need across a staggering and ever-growing number of articles online, researchers and clinicians are clicking on personalized article recommendations delivered by TrendMD’s recommendation widget. TrendMD is a graduate of the UTEST program's third cohort. Using sophisticated algorithms across millions of articles served each month, recommended articles are identified based on keywords and user behaviour, such as click behaviour (“people that read ... Read more
Page 5 of 34« First...34567...102030...Last »